Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CMV-Specific Cytotoxic T-Lymphocytes for CMV Infection After HSCT
NCT02210078Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2015
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in cytomegalovirus infection (CMV), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Success without treatment failure at 4 weeks. Started Feb 2015; status: active, not recruiting.
02
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02210078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210078.